Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutation

Blood Cancer J. 2016 May 13;6(5):e420. doi: 10.1038/bcj.2016.25.

Authors

G F Perini¹, P V Campregher^{1

2}, J S Ross^{2

3}, S Ali², N Hamerschlak¹, F P S Santos¹

Affiliations

¹ Centro de Oncologia e Hematologia Familia Dayan Daycoval, Hospital Israelita Albert Einstein, São Paulo, Brazil.
² Foundation Medicine Inc, Cambridge, MA, USA.
³ Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Everolimus / therapeutic use*
Female
Hodgkin Disease / drug therapy*
Hodgkin Disease / genetics*
Humans
Mutation
Treatment Outcome
Tuberous Sclerosis Complex 2 Protein
Tumor Suppressor Proteins / genetics*

Substances

TSC2 protein, human
Tuberous Sclerosis Complex 2 Protein
Tumor Suppressor Proteins
Everolimus